Management Changes at BioGaia AB

Isabelle Ducellier, Chief Executive Officer has today announced that she has decided to resign from the company and take on the role as Chief Executive Officer of Orkla portfolio company Orkla Health. Isabelle Ducellier will remain in her role until September 30, 2023.

Isabelle Ducellier was appointed as Chief Executive Officer and President effective November 5, 2018 and was before this elected to the BioGaia Board earlier in 2018.

“I am very grateful for these 5 years spent leading BioGaia’s transformation journey into a leading consumer centric probiotic company. I have no doubt that the great team in place will succeed in reaching our ambitious vision to be the most trusted probiotic brand in the world” says Isabelle Ducellier.

The recruitment process for a new Chief Executive Officer has commenced and it is the company’s expectation that the new Chief Executive Officer will be appointed before Isabelle’s departure from the company. Peter Rothschild, Founder and Chairman of BioGaia will continue to remain closely involved in the business and remains available to support the successful BioGaia management team during the transition.

“We are very thankful to Isabelle for her successful efforts to complement the company’s traditional medical marketing model with e-commerce and consumer marketing leading to sustained double-digit growth. She has built a powerful management team leaving the company in its best position ever and I wish her all the best in her new position.” says Peter Rothschild, Chairman of BioGaia.

For additional information please contact:
Peter Rothschild, Chairman of the Board BioGaia, +46 (0)708-30 65 40

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 29, 2023, at 16:45 PM CEST.

Attached documents